NASDAQ:ARDX Ardelyx Q2 2026 Earnings Report $5.03 -0.10 (-1.95%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.12 +0.09 (+1.77%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ardelyx EPS ResultsActual EPSN/AConsensus EPS -$0.05Beat/MissN/AOne Year Ago EPSN/AArdelyx Revenue ResultsActual RevenueN/AExpected Revenue$122.41 millionBeat/MissN/AYoY Revenue GrowthN/AArdelyx Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Ardelyx Earnings HeadlinesArdelyx to Report Second Quarter 2026 Financial Results on August 6, 2026July 23 at 8:01 AM | globenewswire.comComparing Nanobiotix (NASDAQ:NBTX) & Ardelyx (NASDAQ:ARDX)July 23 at 2:44 AM | americanbankingnews.comThey’re still buying the wrong AI stocksTesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be. History shows a similar pattern: Cisco collapsed in 2000, but the internet went on to reshape the world. The lesson applies now as markets question massive AI infrastructure spending. The real opportunity may be Phase 2 AI stocks - companies using AI to dominate cybersecurity, logistics, pharma, and other essential industries.July 26 at 1:00 AM | The Oxford Club (Ad)Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth CatalystsJuly 20, 2026 | insidermonkey.comArdelyx: The Market Is Right To Discount This Revenue GrowthJuly 2, 2026 | seekingalpha.comARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement BattleJune 26, 2026 | finance.yahoo.comSee More Ardelyx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email. Email Address About ArdelyxArdelyx (NASDAQ:ARDX) (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure. Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders. The company is advancing RDX8940, a non‐systemic, gut‐restricted TGR5 agonist intended for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. Additional programs focus on novel mechanisms to manage uremic toxins and intestinal sodium balance, reinforcing Ardelyx’s emphasis on gut‐targeted therapies that may improve patient outcomes without the safety risks of systemic drug exposure. Founded in 2010 and headquartered in San Mateo, California, Ardelyx operates research and development facilities in the Bay Area, with a commercial infrastructure supporting product launch and patient access in the United States. The company has forged strategic collaborations—most notably with Mitsubishi Tanabe Pharma in Japan for the development and commercialization of tenapanor. Ardelyx’s leadership team, led by President and Chief Executive Officer Michael A. Raab, combines experience in drug discovery, regulatory affairs and commercial operations to drive its mission of bringing new treatment options to patients with high unmet medical needs.View Ardelyx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyDefense Earnings Show Readiness Now and Modernization AheadFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
